19 April 2024

08:30 - 09:00

Registration (coffee/tea)

09:00 - 09:10

Welcome (J. Weis, K. Claeys)

09:10 - 10:36

SESSION 1: Motor neuron diseases
Chairpersons: Kristl Claeys, Michael Van Es

Therapeutic (r)evolution in SMA: where are we now and what about the future? - Liesbeth De Waele (Belgium)

Novel developments in ALS - Michael Van Es (The Netherlands)

Oral presentations from abstracts
Bi-allelic ATXN2 repeat expansions cause autosomal, recessive ALS  -Koen Demaegd

The German MND-Net Tissue Bank - an update - Joachim Weis

Risdiplam treatment in adult patients with spinal muscular atrophy: a prospective study investigating clinical, functional, and patient-reported outcome measures over 12 months  - Louise Iterbeke

10:36 - 11:00

Coffee break

11:00 - 12:13

SESSION 2: Neuromuscular junction disorders
Chairpersons: Marc De Baets, Mario Losen

Update on Myasthenia gravis – optimizing treatment for all patientsMartijn Tannemaat (The Netherlands)

Oral presentations from abstracts
Congenital myasthenic syndromes in Belgium: genetic and clinical characterization of pediatric and adult patients - Nathalie Smeets

The relevance of complement activation in myasthenia gravis – a quantification study using the experimental passive transfer MG model - Anja Schöttler

Hock immunization, an update of the experimental autoimmune myasthenia gravis (EAMG) mouse model - Marina Mané Damas

Are thymus-resident plasma cells prognostic factors of thymectomy in patients with anti-acetylcholine receptor myasthenia gravis? - Britt Arets

12:13 - 13:00

A tribute to Prof. J. Michael Schröder, 1937-2023 (Joachim Weis, Stephan Züchner, Claudia Sommer, Vincent Timmerman, Hans-Hilmar Goebel)

13:00 - 14:00


14:00 - 16:39

SESSION 3: Peripheral neuropathies I
Chairpersons: Claudia Sommer, Peter Van den Bergh

New EAN/PNS GBS guideline on the diagnosis and treatment of GBS Pieter Van Doorn (The Netherlands)

Pathophysiology of demyelinating neuropathiesRuth Stassart (Germany)

Genomics-To-Therapy: a concept illustrated by CMT-SORD - Stephan Züchner (USA)

Oral presentations from abstracts
Supervised machine learning algorithms for diagnosing chronic inflammatory demyelinating polyradiculoneuropathy - Iris van Doorn

Loss-of-function mutations in the nuclear envelope gene FAM169A cause autosomal dominant lower and upper motor neuropathy - Maike Dohrn

Recurrent missense variant in ITPR3 causes demyelinating Charcot-Marie-Tooth neuropathy with remarkably variable severity - Danique Beijer

Frequency and clinical characterization of SORD-Related neuropathy in a Belgian cohort - Matthias Opsomer

Dominant OGDH mutations cause peripheral neuropathy with ataxia and optical atrophy - Liedewei Van de Vondel

Let’s drop some Fats: The idiosyncrasies of lipid droplets in iPSC-Schwann cell precursor cells from Charcot-Marie-Tooth disease type 1A patients. - Koen Kuipers

Inducible dental pulp stem cells-derived Schwann cells for CMT1A modelling - Nathalie Dirkx

16:39 - 17:00

Coffee break

17:00 - 19:14

SESSION 4: Peripheral neuropathies II
Chairpersons: Martin Lammens, Stephan Goedee

Novel therapeutic avenues in hereditary peripheral neuropathies - Davide Pareyson (Italy)

Proteostasis regulators in neuromuscular diseases – learning from zebrafish models - Juliane Bremer (Germany)

Oral presentations from abstracts
Comparison of efficacy outcomes with Vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: post-hoc analysis of the HELIOS-A study - Valérie Dupong

A comparison of neurofilament in serum, cerebrospinal fluid and peripheral nerve in patients undergoing nerve biopsy - Simon Streit

Autophagy phenotypical screening identified new molecules to restore neuronal proteostasis in cellular models of HSPB1 and HSPB8-associated peripheral neuropathies - Angela Sisto

The effects of PMP22 overexpression on cellular stress in Charcot-Marie-Tooth disease type 1A - Hanne Jeurissen

PDE4D inhibition with Gebr32a stimulates Schwann cell differentiation and improves the functional outcome in models for Charcot Marie Tooth disease 1A - Tim Vangansewinkel

Foreign body response hampers tissue integration of a poly(ε-caprolactone) nanofibre-containing scaffold for peripheral nerve repair - Pascal Achenbach

Nerve transfers in children with Arthrogryposis Multiplex Congenita - Benedikt Schäfer



20 April 2024

08:30 - 10:33

SESSION 5: Muscle disorders I
Chairpersons: Werner Stenzel, Anne Schänzer

Neuromuscular imaging: a better eye on nerves and musclesNens van Alfen (The Netherlands)

Clinical and imaging advances in inflammatory myopathiesAnneke van der Kooi (The Netherlands)

Whats New in Pathogenesis of IIM Werner Stenzel (Germany)

Oral presentations from abstracts
The adiponectin receptor agonist, ALY688: a promising therapeutic for fibrosis in the dystrophic muscle - Nicolas Dubuisson

Inhibition of KDM5A reverses pathological features in sporadic inclusion body myositis-like cell models - Geert de Vries

Automated morphometric analysis of ICAM-1 expression highlights similarities and differences between myositis subtypes   - Anne Schänzer

10:33 - 11:00

Coffee break

11:00 - 13:05

SESSION 6: Muscle disorders II
Chairpersons: Ingo Kurth, Anneke Van der Kooi

Genetics in distal muscle diseases - Bjarne Udd (Finland)

Advances and caveats of novel therapies in (neuro)muscular disorders Benedikt Schoser (Germany)

Oral presentations from abstracts
Comprehensive four-year disease progression assessment of DM1, based on the Dutch MYODRAFT registry - Leandre la Fontaine

Life expectancy and causes of death in patients with Myotonic Dystrophy type 2. - Alide Tieleman

Heterozygous SPTAN1 loss-of-function variants cause early childhood onset distal myopathy - Jonathan De Winter

The exception that proves the rule: a titin truncating variant causing a dominant myopathy with cardiac involvement - Kristl Claeys

Alpha-synuclein as potential biomarker in Inclusion body myositis – a histological and serological study - Alexander Mensch

13:05 - 13:10

Closure (J. Weis, K. Claeys)